Prime Medicine, Inc. (PRME)

NGM – Real vaqt narxi. Valyuta: USD

3.30

+0.06 (1.85%)

Yopilishda: May 12, 2026, 4:00 PM EDT

07.05.2026

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.4 per share a year ago.

07.05.2026

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2026 and provided a business update.

16.04.2026

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO).

06.03.2026

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

03.03.2026

Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.31 per share a year ago.

03.03.2026

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM359 in CGD; plan to submit BLA following final alignment -- -- Prime Medicine reported cash, cash equivalents, investments, and restricted cash of $191M providing cash runway into 2027 -- CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2025 and provided a business update.

25.02.2026

Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences:

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

16.04.2026

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

03.03.2026

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

07.12.2025

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2 clinical data with PM359, the Company's investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease (CGD) in the New England Journal of Medicine (NEJM). The data will also be presented in a poster session at the 67th American Society of Hematology (ASH) Annual Meeting, December 6-9, 2025 in Orlando, Florida.

Prime Medicine, Inc. (PRME)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Prime Medicine, Inc. (PRME)

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine to Participate in Upcoming Investor Conferences

Videolar

No Data

Press-relizlar

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine to Participate in Upcoming Investor Conferences

Videolar

No Data

Press-relizlar

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Search stocks

Prime Medicine, Inc. (PRME)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Prime Medicine, Inc. (PRME)

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine to Participate in Upcoming Investor Conferences

Videolar

No Data

Press-relizlar

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine to Participate in Upcoming Investor Conferences

Videolar

No Data

Press-relizlar

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease